The effect of AlgaSense® on the stress response and mental wellbeing in young adults: The Stress Examination: Relief Effects with Nutritional AlgaSense® (SERENAL) study - SERENAL study

Start Date03 Jun 2024

Sponsor / Collaborator

BioActor BV

100 Clinical Results associated with Oxazolam

100 Translational Medicine associated with Oxazolam

100 Patents (Medical) associated with Oxazolam

Literatures (Medical) associated with Oxazolam

01 Aug 2023·Journal of Taibah University Medical Sciences

Antidiabetes study of Spondias mombin (Linn) stem bark fractions in high-sucrose diet-induced diabetes in Drosophila melanogaster

Article

Author: Saliu, Jamiyu A ; Saibu, Oluwatosin A ; Omoboyowa, Damilola A ; Shodehinde, Sidiqat A ; Agoi, Mary D

ObjectiveThe onset of insulin resistant diabetes has been associated with a high-sucrose diet in vertebrates and invertebrates. However, various parts of Spondias mombin reportedly possess antidiabetic potential. However, the antidiabetic efficacy of S. mombin stem bark in high-sucrose diet-induced Drosophila melanogaster model has not been explored. In this study, the antidiabetic and antioxidant effects of the solvent fractions of S. mombin stem bark were evaluated using in vitro, in vivo, and in silico methods.MethodsSuccessive fractionation of S. mombin stem bark ethanol extract was performed; the resulting fractions were subjected to in vitro antioxidant and antidiabetic assays using standard protocols. The active compounds identified from the high-performance liquid chromatography (HPLC) study of the n-butanol fraction were docked against the active site of Drosophila α-amylase using AutoDoc Vina. The n-butanol and ethyl acetate fractions of the plant were incorporated into the diet of diabetic and nondiabetic flies to study the in vivo antidiabetic and antioxidant properties.ResultsThe results obtained revealed that n-butanol and ethyl acetate fractions had the highest in vitro anti-oxidant capacity by inhibiting 2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing antioxidant power, and hydroxyl radical followed by significant inhibition of α-amylase. HPLC analysis revealed the identification of eight compounds with quercetin having the highest peak followed by rutin, rhamnetin, chlorogenic acid, zeinoxanthin, lutin, isoquercetin, and rutinose showing the lowest peak. The fractions restored the glucose and antioxidant imbalance in diabetic flies, which is comparable with the standard drug (metformin). The fractions were also able to upregulate the mRNA expression of insulin-like peptide 2, insulin receptor, and ecdysone-inducible gene 2 in diabetic flies. The in silico studies revealed the inhibitory potential of active compounds against α-amylase with isoquercetin, rhamnetin, rutin, quercetin, and chlorogenic acid having higher binding affinity than the standard drug (acarbose).ConclusionOverall, the butanol and ethyl acetate fractions of S. mombin stem bark ameliorate type 2 diabetes in Drosophila. However, further studies are needed in other animal models to confirm the antidiabetes effect of the plant.

01 Feb 2020·Toxicology in VitroQ3 · MEDICINE

Silk fibroin/hydroxyapatite composite membranes: Production, characterization and toxicity evaluation

Q3 · MEDICINE

Article

Author: Coelho, Fernanda ; Cilli, Eduardo Maffud ; Scarel-Caminaga, Raquel Mantuaneli ; de Oliveira Capote, Ticiana Sidorenko ; Cavicchioli, Mauricio ; Lima Ribeiro, Sidney José ; Specian, Sybele Saska

Alloplastic materials based on biopolymers such as silk fibroin (SF) have provided the synthesis of excellent biomaterials for bone repair. The aim of the present study was to produce SF membranes associated to hydroxyapatite (HA) and evaluate their physicochemical characteristics and the toxicity potential. After obtaining the SF, the HPLC was executed to verify the elimitation of serecin, a toxic protein of the silk, and the cytotoxicity assay was assessed in the subtances from the SF processing. SF and SF-HA membranes were evaluated by SEM, EDS, FTIR, mechanical properties and toxicity (cytotoxicity, genotoxicity and mutagenic effects). The serecin was elimined in the SF process, and its cytotoxicity was confirmed. SF and SF-HA membranes presented interesting results based on the physicochemical characterization. SF membrane showed cytotoxic, genotoxic and mutagenic effects. In conclusion, SF and SF-HA membranes presented adequate mechanical resistance to act respectively as wound healing or bone filling materials, and they were hydrophilic. SF-HA membrane did not present any toxic potential and allowed cell adhesion and proliferation. The unexpected cyto/genotoxicity and mutagenic effect of SF evidenced the importance of investigating the toxic potential of biomaterials, mainly those in contact with human body for prolonged time.

01 Jan 2020·PharmacologyQ4 · MEDICINE

Pharmacological Characteristics of Anxiolytics on Acetylcholine-Induced Contractions in Rat Detrusor Smooth Muscle

Q4 · MEDICINE

Article

Author: Yamaki, Fumiko ; Yoshio, Takashi ; Tanaka, Yoshio ; Shimada, Toma ; Horiguchi, Saki ; Matsuo, Kazuhiro ; Ao, Lin ; Obara, Keisuke ; Ikarashi, Takumi ; Yoshioka, Kento ; Ogawa, Tsukasa

Introduction: Benzodiazepine anxiolytics are believed to cause urination disorders due to their anticholinergic effects. Objective: This study was carried out to investigate the potential inhibitory effects of 15 clinically available anxiolytics in Japan on acetylcholine (ACh)-induced contractions in rat detrusor smooth muscle (DSM) to predict whether these anxiolytics could induce urination disorders. Methods: Effects of anxiolytics on contractions induced by ACh and 80 mmol/L KCl solution in rat DSM and effects of anxiolytics on specific binding of [N-methyl-3H]scopolamine ([3H]NMS) in mouse cerebral cortex were investigated. Results and Conclusions: ACh-induced contractions in rat DSM were inhibited by clotiazepam and diazepam (benzodiazepine anxiolytics) at concentrations that were clinically relevant. These contractions were also significantly inhibited by paroxetine, escitalopram (selective serotonin reuptake inhibitors [SSRIs]), and hydroxyzine (a histamine H1 receptor antagonist), albeit at concentrations that substantially exceeded clinically achievable blood levels. At a concentration of 10–5 mol/L, paroxetine, escitalopram, and hydroxyzine inhibited 80 mmol/L high-KCl solution-induced rat DSM contractions but not clotiazepam and diazepam. Paroxetine, escitalopram, and hydroxyzine also inhibited specific binding of [3H]NMS in mouse cerebral cortex but clotiazepam and diazepam did not. In contrast to the effects of the abovementioned anxiolytics, ACh-induced contractions were not significantly affected by tofisopam, alprazolam, lorazepam, bromazepam, oxazolam, chlordiazepoxide, clonazepam, ethyl loflazepate (benzodiazepine anxiolytics), fluvoxamine (an SSRI), or tandospirone (a serotonin 5-HT1A receptor agonist). These findings suggest that most clinically used anxiolytics are not likely to result in anticholinergic-induced urination disorders within their clinically achievable blood concentration ranges. However, clotiazepam and diazepam may induce urination disorders within their clinical dose ranges via nonanticholinergic inhibition of DSM contractility.

100 Deals associated with Oxazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D01278	Oxazolam	N03AE N05CD N05BA	DB15491

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anxiety Disorders	JP	Alfresa Pharma Corp.	11 Sep 1970
Catatonia	JP	Alfresa Pharma Corp.	11 Sep 1970
Depressive Disorder	JP	Alfresa Pharma Corp.	11 Sep 1970
Neurotic Disorders	JP	Alfresa Pharma Corp.	11 Sep 1970

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis